Cystic Fibrosis Clinical Trial
Official title:
A Pilot Study to Evaluate the Use of the MN4000 for Treatment of Cystic Fibrosis (CF) and Motor Neuron Disease (MND) Patients in the Home Setting
The study was a non-randomized open label pilot study. It was an observational design
conducted at one (1) site in the US. All enrolled subjects received treatment with the
MN4000.
This pilot study evaluated subject satisfaction with the therapy and adherence to the therapy
during the 90-day treatment period, and also collected clinical outcome data. Outcomes were
assessed before, during and after the MN4000 treatment period.
The study was a non-randomized open label pilot study. It was an observational design
conducted at one (1) site in the US. All enrolled subjects received treatment with the
MN4000.
This pilot study evaluated subject satisfaction with the therapy and adherence to the therapy
during the 90-day treatment period, and also collected clinical outcome data. Outcomes were
assessed before, during and after the MN4000 treatment period. The study did not include a
control group. This pilot study was designed to provide initial information that could inform
decisions for future larger-scale studies.
Ten (10) patients total were enrolled from CF and NMD clinics. Eligible subjects were adult
patients who were able to perform MN4000 therapy using a mouthpiece and who met all inclusion
and none of the exclusion criteria.
All patients received therapy with the MN4000 following the labeled instructions for the
device.
The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to
market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary
secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device,
cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The
MetaNeb® 4 System with application for homecare environment. It is commercially marketed as
the MN4000. The device consists of a pneumatic compressor and an air pulse generator that
delivers CHFO and CPEP to;
1. facilitate clearance of mucous from the lungs;
2. provide lung expansion therapy and;
3. enhance delivery of aerosol therapy.
This "triple" mode device can provide aerosol therapy while alternating between CPEP for lung
expansion and CHFO for airway clearance. Supplemental oxygen therapy may also be delivered
when used with compressed oxygen.
The MN4000 has three therapy modes:
- CHFO (Continuous High Frequency Oscillation) - delivers aerosol therapy while providing
oscillating pressure pulses to the airway
- CPEP (Continuous Positive Expiratory Pressure) - delivers aerosol therapy while
providing continuous positive pressure to help hold open and expand the airways
- Aerosol - for delivery of aerosol only. In this mode, CHFO and CPEP are not available
After assessing baseline status, therapy with the MN4000 was introduced and incorporated into
the daily home respiratory care treatment regimen for all patients.
Other airway clearance and/or lung expansion therapies were not to be performed during the
three-month study period. The treatment regimen for other respiratory care modalities (e.g.
aerosolized medications) was that which was prescribed by the patient's health care team in
the routine standard care of each patient.
During the three-month follow-up period, adherence to the daily prescribed therapy regimen
was assessed. Subjects/caregivers were asked to provide adherence information for each day
during the 90-day study period.
Documentation of efficacy and safety Variables was completed by study staff at the time of
occurrence, from review of the patient's medical records and from scores and rankings for
questionnaires.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |